On Oct 23, major Wall Street analysts update their ratings for $Quest Diagnostics (DGX.US)$, with price targets ranging from $165 to $185.
BofA Securities analyst Michael Ryskin maintains with a buy rating, and sets the target price at $179.
Citi analyst Patrick B Donnelly maintains with a buy rating, and adjusts the target price from $165 to $185.
Barclays analyst Stephanie Davis maintains with a hold rating, and adjusts the target price from $154 to $168.
Evercore analyst Elizabeth Anderson CFA maintains with a hold rating, and maintains the target price at $165.
Mizuho Securities analyst Ann Hynes maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Quest Diagnostics (DGX.US)$'s main analysts recently are as follows:
The integration of LifeLabs and consistent elevated utilization trends are the main factors behind the updated guidance for Quest Diagnostics. The company's defensive characteristics, especially during an election cycle, and more secure estimates for future years remain positive aspects highlighted by analysts.
Quest Diagnostics delivered a strong performance in the third quarter, exceeding expectations. The company maintained its earnings forecast even in the face of challenges posed by hurricanes. Additionally, preliminary insights regarding the fiscal year 2025 appear promising.
The laboratory sector is viewed favorably for the year 2025, with the belief that it is unnecessary to shy away from an investment due to cost considerations when compared to alternatives. Quest Diagnostics is seen as having a series of drivers that will contribute to expedited growth in 2025. Notably, the company's growth is expected to continue due to the completion of eight acquisitions in the preceding year.
Here are the latest investment ratings and price targets for $Quest Diagnostics (DGX.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月23日，多家华尔街大行更新了$奎斯特诊疗 (DGX.US)$的评级，目标价介于165美元至185美元。
美银证券分析师Michael Ryskin维持买入评级，目标价179美元。
花旗分析师Patrick B Donnelly维持买入评级，并将目标价从165美元上调至185美元。
巴克莱银行分析师Stephanie Davis维持持有评级，并将目标价从154美元上调至168美元。
Evercore分析师Elizabeth Anderson CFA维持持有评级，维持目标价165美元。
瑞穗证券分析师Ann Hynes维持买入评级。
此外，综合报道，$奎斯特诊疗 (DGX.US)$近期主要分析师观点如下：
LifeLabs的整合和持续增长的利用率趋势是更新奎斯特诊疗指引背后的主要因素。该公司的防御特性，尤其是在选举周期期间，以及对未来几年更加安全的估计，仍然是分析师强调的积极方面。
奎斯特诊疗第三季度表现强劲，超出预期。即使面临飓风带来的挑战，该公司仍然保持其盈利预测。此外，关于2025财年的初步见解看起来令人鼓舞。
实验室板块在2025年被认为是有利的，人们相信与其他替代方案相比，在投资上没有必要因为成本考虑而退缩。奎斯特诊疗被视为有一系列推动力，将有助于2025年的快速增长。值得注意的是，由于在前一年完成了八项收购，该公司的增长预计将继续。
以下为今日7位分析师对$奎斯特诊疗 (DGX.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
